Biomea Fusion Stock (NASDAQ:BMEA)

Forecast Revenue Ownership Financials Chart

Previous Close

$1.42

52W Range

$1.29 - $12.18

50D Avg

$1.85

200D Avg

$2.27

Market Cap

$82.10M

Avg Vol (3M)

$1.65M

Beta

-0.14

Div Yield

BMEA Company Profile

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Apr 16, 2021

Website

BMEA Performance

BMEA Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-144.07M	$-126.14M	$-83.63M
Net Income	$-138.43M	$-117.25M	$-80.02M
EBITDA	$-144.07M	$-124.62M	$-82.94M
Basic EPS	$-3.83	$-3.44	$-2.73
Diluted EPS	$-3.83	$-3.44	$-2.73

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
ZNTL	Zentalis Pharmaceuticals, Inc.
SPRB	Spruce Biosciences, Inc.
SRZN	Surrozen, Inc.
GUTS	Fractyl Health, Inc. Common Stock
ALXO	ALX Oncology Holdings Inc.
PLRX	Pliant Therapeutics, Inc.
CNTB	Connect Biopharma Holdings Limited
ATYR	aTyr Pharma, Inc.
ACET	Adicet Bio, Inc.
ADVM	Adverum Biotechnologies, Inc.